Biotechnology & Life Sciences M&A Transactions

United Therapeutics acquires Thymmune Therapeutics, enhancing its regenerative medicine and cell therapy capabilities with a $300 million deal including earn-outs.

Ipsen to acquire Memo Therapeutics AG for up to €700M, gaining a Phase II antibody for BKPyV. Kurma Partners and Eurazeo Group are key stakeholders in this significant biotech deal.

Tradebe strengthens its Life Sciences division by acquiring CitraSource, a U.S.-based citrus ingredient processor, marking its second U.S. acquisition in the sector.

Caidya

Caidya and Simbec-Orion combine forces, forming a specialized CRO to streamline drug development from early science to global clinical trials.

Ipsen secures Kartos Therapeutics' navtemadlin in a deal up to $1.75B, enhancing its hemato-oncology pipeline with a promising myelofibrosis treatment.

Ipsen secures navtemadlin, a novel myelofibrosis therapy, in a deal valued up to $1.3 billion, targeting unmet needs in rare blood cancers.

Agilent Technologies completes Biocare Medical acquisition, enhancing its diagnostics and pathology offerings. Learn about the strategic implications.

Thalia Therapeutics

UK biotech Thalia Therapeutics secures €3.1 million and acquires Sanmirna Therapeutics, enhancing its RNA-based oncology and cardiovascular drug development.

Boundless Bio

Boundless Bio and Serapha Bio unite in a merger, raising $230 million to pioneer a gene editing therapy for Alpha-1 Antitrypsin Deficiency.

Model N strengthens 340B and gross-to-net revenue management with Kalderos acquisition, offering enhanced compliance and revenue reconciliation for life sciences.

AbbVie nears $10.9 billion deal for Apogee Therapeutics, boosting its inflammatory disease pipeline with a long-acting drug candidate. Industry M&A heats up.

Biogen strengthens its immunology pipeline by acquiring RayThera for up to $1 billion, gaining access to promising small-molecule therapies for immune-mediated diseases.